Resourcing, annotating, and analysing synthetic peptides of SARS‐CoV‐2 for immunopeptidomics and other immunological studies

SARS‐CoV‐2 has caused a significant ongoing pandemic worldwide. A number of studies have examined the T cell mediated immune responses against SARS‐CoV‐2, identifying potential T cell epitopes derived from the SARS‐CoV‐2 proteome. Such studies will aid in identifying targets for vaccination and immune monitoring. In this study, we applied tandem mass spectrometry and proteomic techniques to a library of ∼40,000 synthetic peptides, in order to generate a large dataset of SARS‐CoV‐2 derived peptide MS/MS spectra. On this basis, we built an online knowledgebase, termed virusMS (https://virusms.erc.monash.edu/), to document, annotate and analyse these synthetic peptides and their spectral information. VirusMS incorporates a user‐friendly interface to facilitate searching, browsing and downloading the database content. Detailed annotations of the peptides, including experimental information, peptide modifications, predicted peptide‐HLA (human leukocyte antigen) binding affinities, and peptide MS/MS spectral data, are provided in virusMS.

[1]  L. Cosmi,et al.  Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients , 2020, European journal of immunology.

[2]  Jingqiu Cheng,et al.  Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins , 2020, Molecular & Cellular Proteomics.

[3]  R. V. van Lier,et al.  Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients , 2020, European journal of immunology.

[4]  Jennifer G. Abelin,et al.  SARS-CoV-2 infected cells present HLA-I peptides from canonical and out-of-frame ORFs , 2020, bioRxiv.

[5]  H. Rammensee,et al.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.

[6]  R. Cox,et al.  Not just antibodies: B cells and T cells mediate immunity to COVID-19 , 2020, Nature Reviews Immunology.

[7]  P. Doherty,et al.  Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype , 2020, Proceedings of the National Academy of Sciences.

[8]  Jiyuan Zhang,et al.  Single-cell landscape of immunological responses in patients with COVID-19 , 2020, Nature Immunology.

[9]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[10]  Zeyu Chen,et al.  T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.

[11]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[12]  Nichollas E. Scott,et al.  Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 , 2020, Nature Medicine.

[13]  G. Preston,et al.  Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease , 2020, Journal of proteome research.

[14]  Y. Al-Abed,et al.  Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics , 2020, Future medicinal chemistry.

[15]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[16]  C. Poh,et al.  Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients , 2020, Nature Communications.

[17]  J. Armengaud,et al.  Shortlisting SARS‐CoV‐2 Peptides for Targeted Studies from Experimental Data‐Dependent Acquisition Tandem Mass Spectrometry Data , 2020, Proteomics.

[18]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[19]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[20]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[21]  C. June,et al.  Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 , 2020, Cancer discovery.

[22]  Huanhuan Gao,et al.  Proteomic and Metabolomic Characterization of COVID-19 Patient Sera , 2020, Cell.

[23]  Qiu Zhao,et al.  Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  N. Bashir,et al.  Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options , 2020, Journal of Clinical Microbiology.

[25]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[26]  L. Gostin,et al.  The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. , 2020, JAMA.

[27]  Amos Bairoch,et al.  The neXtProt knowledgebase in 2020: data, tools and usability improvements , 2019, Nucleic Acids Res..

[28]  Yasset Perez-Riverol,et al.  The ProteomeXchange consortium in 2020: enabling ‘big data’ approaches in proteomics , 2019, Nucleic Acids Res..

[29]  Sri H. Ramarathinam,et al.  Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics , 2019, Nature Protocols.

[30]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[31]  The UniProt Consortium,et al.  UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..

[32]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[33]  M. Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[34]  S. Turner,et al.  T cell mediated immunity to influenza: mechanisms of viral control. , 2014, Trends in immunology.

[35]  Jincun Zhao,et al.  T cell-mediated immune response to respiratory coronaviruses , 2014, Immunologic Research.

[36]  Hidde L. Ploegh,et al.  The known unknowns of antigen processing and presentation , 2008, Nature Reviews Immunology.

[37]  F. Penin,et al.  Memory T-Cell-Mediated Immune Responses Specific to an Alternative Core Protein in Hepatitis C Virus Infection , 2004, Journal of Virology.

[38]  Florian Reisinger,et al.  ProteomeXchange consortium , 2013 .

[39]  O. Lund,et al.  Access the most recent version at doi: 10.1110/ps.0239403 References , 2002 .

[40]  C. Watts,et al.  Pathways of antigen processing and presentation. , 1999, Reviews in immunogenetics.